Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03391414 · ClinicalTrials.gov registry record · Phase 1

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

A Phase 1 study of Cystic Fibrosis, sponsored by Joseph Pilewski.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
2
Study locations

NCT03391414: Completed Phase 1 study of Cystic Fibrosis, sponsored by Joseph Pilewski.

NCT03391414 is a Phase 1 study of Cystic Fibrosis that has completed, run by Joseph Pilewski. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03391414, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Joseph Pilewski.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

This study will compare the use of inhaled concentrated sodium chloride solution to an inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking at whether or not it is possible to decrease the acidity of the airways by inhaling sodium bicarbonate through nebulizer treatments.

Primary Outcome

Change in pH after inhalation of two doses on one day

Conditions Studied

Interventions

  • DRUG hypertonic bicarbonate
  • DRUG sodium chloride

Study Locations (2)

Pennsylvania

  • UPMC Fallk Clinic - Pittsburgh
  • Children's Hospital of Pittsburgh of UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2014-08
Est. Completion 2016-07
Phase Phase 1
Joseph Pilewski

1 total trials

What the finished NCT03391414 record still lists

NCT03391414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which hypertonic bicarbonate is the first listed.

NCT03391414 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03391414 about?

NCT03391414 is a clinical study titled "Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis". This study will compare the use of inhaled concentrated sodium chloride solution to an inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking at whether or not it is po...

What is the current status of trial NCT03391414?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-08. Estimated completion is 2016-07.

What conditions does trial NCT03391414 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT03391414?

The interventions under investigation include: hypertonic bicarbonate (DRUG), sodium chloride (DRUG).

Who is sponsoring clinical trial NCT03391414?

This trial is sponsored by Joseph Pilewski, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03391414 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03391414's enrollment target sits among peer trials

12 152nd of 169 higher than 15 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03391414, the US trial registry maintained by the National Library of Medicine. NCT03391414 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.